BioPharma Drug Discovery

US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD

Key Highlights: US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major mil...

 May 27, 2022 | News

Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts

HotSpot Therapeutics plans to deploy data from Excelra's flagship product GOSTAR toward select protein targets to augment its allosteric inhibitor candidat...

 May 26, 2022 | News

Eurofins Discovery Announces Formation of its New Scientific Advisory Board

The SAB is tasked with providing guidance on industry trends, growth opportunities and innovations that will further strengthen Eurofins Discovery's portfo...

 May 25, 2022 | News

FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

"As researchers and clinicians have gained knowledge about eosinophilic esophagitis in recent years, more cases of the disorder have been recognized and di...

 May 23, 2022 | News

BD and Mitsubishi Gas Chemical Have Signed a Letter Of Intent (LOI) to Discuss a Partnership Agreement to Explore New Ways to Advance Biologic Drug Delivery

 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Mitsubishi Gas Chemical Company, Inc. ...

 May 18, 2022 | News

New therapeutic option to reduce risk of cardiovascular deaths and repeated hospitalizations among adult heart failure patients approved in Singapore

Over the course of the VICTORIA study, there was a 4.2% reduction in annualized absolute risk with VERQUVO™ (vericiguat) compared with pl...

 May 18, 2022 | News

Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI

The joint research project will leverage high performance computing technologies and the supercomputer Fugaku to accelerate simulation integrated AI that c...

 May 17, 2022 | News

GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

 GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter referred to as "GeneQuantum"), a global innovative biotechnology company dedicated to the deve...

 May 16, 2022 | News

A novel universal antiviral drug introduced in Korea

 The birth of a universal antiviral drug with a mechanism applicable to all viral infections is approaching.   This antiviral agent, developed ...

 May 13, 2022 | News

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

The 2022 CSCO Guidelines incorporate a total of four selinexor combination therapy regimens for relapsed myeloma. In addition, the guidelines also recommen...

 May 13, 2022 | News

TIKOMED and IQVIA announce a strategic collaboration

Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead ...

 May 06, 2022 | News

BD to Showcase its Deep Commitment to Drug Delivery Excellence at Pharmapack

The return to in-person meetings provides us with the opportunity to welcome you back to the BD booth -- which will show our wide range of services an...

 May 04, 2022 | News

FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial

The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the FDA for an EV...

 April 28, 2022 | News

Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004

LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psori...

 April 25, 2022 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in